Table 1.
Nonrandomized studies of RDP
| a)≤ 1 year follow-up | |||||
|---|---|---|---|---|---|
| N | Induction | Maintenance | 1-Year AR rate | 1-Yr GS | Ref # |
| 57 | Dacluzimab | CSA-MMF | 25% | 89% | 44 |
| 301 | ATG | CSA-SRL | 4.9% | 91% | 45 |
| 77 | __________ | TAC-SRL | 13% | 100% | 46 |
| 130 | Basiliximab | CSA-MMF | 19%* | 97% | 47 |
| b) > 1 year follow-up | ||||||
|---|---|---|---|---|---|---|
| N | Antibody | Maintenance | 1-Year AR rate | 1-Yr GS | Long-Term GS | Ref # |
| 100 | ATG | CSA-MMF | ___ | 97% | 82% @ 4 Yrs | 31 |
| 84 | ATG | TAC-MMF-SRL | 11% | 96% | 93% @ 2.5 Yrs | 48 |
| 775 | ATG | CSA-MMF or TAC-SRL | 13% | 95% | 80% @ 4 Yrs | 50 |
| 116 | Basiliximab | TAC-MMF | ___ | 97% | 90% @ 6 Yrs | 52 |
*
higher in ABO incompatible vs. compatible.
AR = acute rejection rate; GS = graft survival rate; ATG = thymoglobulin; CSA = cyclosporine MMF = mycophenolate mofitil; TAC = tacrolimus